Last updated on November 2019

Dose Optimization Study of Idelalisib in Follicular Lymphoma


Brief description of study

The primary objective of this study is to establish a safe and effective dosing regimen of idelalisib in participants with relapsed or refractory follicular lymphoma (FL) who have no other therapeutic options.

Clinical Study Identifier: NCT02536300

Find a site near you

Start Over

Pacific Shores Medical Group

Long Beach, CA United States
  Connect »

The Tweed Hospital

Tweed Heads, Australia
  Connect »

Calvary Hospital

North Adelaide, Australia
  Connect »

Box Hill Hospital

Box Hill, Australia
  Connect »

Alfred Health

Melbourne, Australia
  Connect »

Fraser Clinical Trials, Inc

New Westminster, BC Canada
  Connect »

Hopital Saint Antoine

Paris Cedex 12, France
  Connect »

Hopital Saint Louis

Paris Cedex 12, France
  Connect »

Centre Hospitalier Lyon Sud

Pierre Bénite Cedex, France
  Connect »

C.H.U. de Poitiers

Poitiers Cedex, France
  Connect »

Institut Catala d'Oncologia

L'Hospitalet de Llobregat, Spain
  Connect »

Hospital Son Llatzer

Palma de Mallorca, Spain
  Connect »

Kent and Canterbury Hospital

Canterbury, United Kingdom
  Connect »

Hillingdon Hospital

London, United Kingdom
  Connect »

Royal Oldham Hospital

Oldham, United Kingdom
  Connect »

Raigmore Hospital

Inverness, United Kingdom
  Connect »

Barts Health NHS Trust

London, United Kingdom
  Connect »

Centre Hospitalier Lyon Sud

Pierre Bénite Cedex, France
  Connect »

McFarland Clinic PC

Ames, IA United States
  Connect »

Hematology Oncology Clinic

Baton Rouge, LA United States
  Connect »

Centre Hospitalier Lyon Sud

Pierre Bénite Cedex, France
  Connect »